tiprankstipranks
Trending News
More News >
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Advertisement

Catalyst Pharma (CPRX) AI Stock Analysis

Compare
2,350 Followers

Top Page

CPRX

Catalyst Pharma

(NASDAQ:CPRX)

Rating:76Outperform
Price Target:
$22.00
▲(12.02% Upside)
Catalyst Pharma's strong financial performance and positive earnings call sentiment are the primary drivers of the stock score. The company's robust revenue growth, solid balance sheet, and strategic advancements in key products outweigh the bearish technical indicators and valuation concerns. The stock is well-positioned for growth, though investors should monitor technical trends and competitive pressures.
Positive Factors
Product Launch
Agamree launch strength exceeds early expectations while Fycompa holds firm ahead of LOE.
Revenue
Catalyst reported strong revenue across each of their commercial products.
Negative Factors
Generic Competition
Commercial performance post generic entry is cited as the most significant unknown that could impact their total product guidance.
Product Decline
The franchise is expected to decline more meaningfully as generic availability expands.

Catalyst Pharma (CPRX) vs. SPDR S&P 500 ETF (SPY)

Catalyst Pharma Business Overview & Revenue Model

Company DescriptionCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
How the Company Makes MoneyCatalyst Pharma generates revenue primarily through the sale of its flagship product, Firdapse, which is distributed to patients suffering from Lambert-Eaton Myasthenic Syndrome (LEMS). The company also explores opportunities to expand the use of Firdapse through clinical trials and potential new indications, which could increase its market reach and revenue potential. Additionally, Catalyst Pharma may enter into strategic partnerships or licensing agreements that can provide upfront payments, milestone payments, and royalties, further contributing to its earnings. The company's financial success is influenced by its ability to market its products effectively, expand its product line, and navigate the regulatory environment for rare disease treatments.

Catalyst Pharma Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: -9.87%|
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
Catalyst Pharmaceuticals reported strong revenue growth and cash position, driven by impressive performance in their key products FIRDAPSE and AGAMREE. However, challenges such as FYCOMPA's revenue decline due to generic competition and increased SG&A expenses were noted. Overall, the highlights of strong growth and strategic advancements significantly outweigh these challenges.
Q2-2025 Updates
Positive Updates
Record-Setting Revenue Growth
Total revenue for Q2 2025 reached $146.6 million, a 19.4% increase year-over-year. Year-to-date, total revenue grew 30.2% to $288 million.
Strong Performance of FIRDAPSE
FIRDAPSE generated net product revenue of $84.8 million in Q2 2025, a growth of $7.5 million versus Q2 2024. Year-to-date revenue is $168.6 million, up 16.9% over the first half of 2024.
AGAMREE's Impressive Growth
AGAMREE achieved $27.4 million in net product revenue in Q2 2025, a 213% increase year-over-year. First half net revenues reached $49.4 million, up 398% from the prior year.
Strong Cash Position
Catalyst ended the second quarter with a cash position of $652.8 million, an increase of $135.2 million from December 31, 2024.
New Leadership and Expansion Strategy
Dr. Will Andrews joined as Chief Medical Officer, and Dr. Dan Curran joined the Board of Directors, enhancing leadership in rare diseases.
Negative Updates
FYCOMPA Revenue Decline
FYCOMPA's revenue in Q2 2025 was $34.3 million, reflecting a year-over-year decrease of 6%. First half 2025 revenue reached $70 million, up 4.5% from the same period last year, with anticipated impact from generic competition.
Increased SG&A Expenses
Selling, general, and administrative expenses for Q2 2025 increased to $45.9 million from $40.7 million in Q2 2024, driven by increased personnel costs.
Patent Litigation Uncertainty
Catalyst is awaiting a trial date in ongoing patent litigation for FIRDAPSE, with more clarity expected after the Markman hearing scheduled for October 7, 2025.
Company Guidance
During the Catalyst Pharmaceuticals Q2 2025 financial results call, the company's leadership provided comprehensive guidance on various metrics. Total revenue for Q2 2025 reached $146.6 million, marking a year-over-year increase of 19.4%. The first half of 2025 saw total revenue grow by 30.2% to $288 million. The company ended the quarter with a cash position of $652.8 million. Catalyst reaffirmed its full-year 2025 revenue guidance of $545 million to $565 million, with specific guidance for FIRDAPSE set at $355 million to $360 million, AGAMREE between $100 million and $110 million, and FYCOMPA at $90 million to $95 million. FIRDAPSE achieved $84.8 million in Q2 net product revenue, growing 16.9% in the first half of 2025 compared to the same period in 2024. AGAMREE generated $27.4 million in Q2 revenue, a 213% year-over-year increase, driven by a 90% patient retention rate. FYCOMPA's Q2 revenue was $34.3 million, despite a 6% year-over-year decline due to anticipated generic competition. The company reported a GAAP net income of $52.1 million, a 27.7% increase from Q2 2024. Non-GAAP net income was $86.4 million, equating to $0.68 per diluted share. Catalyst's strategy focuses on expanding FIRDAPSE's market presence, particularly in the oncology segment, and sustaining AGAMREE's adoption as a leading treatment for Duchenne Muscular Dystrophy.

Catalyst Pharma Financial Statement Overview

Summary
Catalyst Pharma's financial statements reflect strong revenue growth and robust margins. The balance sheet is solid, characterized by low leverage and high liquidity, supporting financial stability. The cash flow statement shows strong cash generation, though past volatility in free cash flow should be monitored. Overall, the company is well-positioned financially, with potential for continued growth and profitability.
Income Statement
92
Very Positive
Catalyst Pharma has demonstrated strong revenue growth, with a significant increase in total revenue from $398.2 million in 2023 to $491.7 million in 2024, marking a growth rate of approximately 23.4%. The company maintains a high gross profit margin of 100% due to its cost structure. The net profit margin improved from 17.9% in 2023 to 33.3% in 2024, indicating enhanced profitability. The EBIT and EBITDA margins are robust at 39.7%, showcasing efficient operational performance. Overall, the income statement reflects strong growth and profitability.
Balance Sheet
88
Very Positive
Catalyst Pharma exhibits a strong balance sheet with a low debt-to-equity ratio of 0.004, reflecting minimal leverage. The return on equity (ROE) is impressive at 22.5%, indicating effective use of equity capital to generate profits. The equity ratio is robust at 85.5%, demonstrating a solid equity base relative to total assets. The company's financial stability is reinforced by substantial cash and short-term investments, significantly exceeding its total debt, contributing to a healthy liquidity position.
Cash Flow
75
Positive
The company has shown strong cash flow generation with a significant increase in free cash flow from -$54.9 million in 2023 to $143.4 million in 2024. The operating cash flow to net income ratio is 0.88, indicating efficient cash conversion from net income. The free cash flow to net income ratio is 0.88, suggesting a strong ability to generate cash relative to earnings. However, the lack of positive free cash flow growth in previous years indicates potential volatility in cash flow generation.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue534.65M491.73M398.20M214.20M140.83M119.07M
Gross Profit441.72M422.89M313.67M179.81M118.95M102.03M
EBITDA250.28M232.90M119.69M101.84M52.38M41.30M
Net Income197.35M163.89M71.41M83.08M39.48M74.98M
Balance Sheet
Total Assets908.87M851.41M470.11M375.63M237.79M192.35M
Cash, Cash Equivalents and Short-Term Investments580.66M517.55M137.64M298.39M191.27M140.28M
Total Debt3.09M3.19M3.56M3.89M3.89M28.77K
Total Liabilities114.59M123.78M82.23M75.21M30.96M22.76M
Stockholders Equity794.28M727.63M387.88M300.42M206.83M169.60M
Cash Flow
Free Cash Flow267.57M239.25M-54.92M116.02M59.35M45.02M
Operating Cash Flow267.93M239.81M143.60M116.05M60.37M45.03M
Investing Cash Flow-357.00K-556.00K-293.50M9.21M-11.02M-5.01M
Financing Cash Flow2.68M140.66M-10.86M1.69M-8.14M701.93K

Catalyst Pharma Technical Analysis

Technical Analysis Sentiment
Negative
Last Price19.64
Price Trends
50DMA
22.46
Negative
100DMA
23.02
Negative
200DMA
22.49
Negative
Market Momentum
MACD
-0.29
Negative
RSI
34.29
Neutral
STOCH
57.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPRX, the sentiment is Negative. The current price of 19.64 is below the 20-day moving average (MA) of 21.22, below the 50-day MA of 22.46, and below the 200-day MA of 22.49, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 34.29 is Neutral, neither overbought nor oversold. The STOCH value of 57.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPRX.

Catalyst Pharma Risk Analysis

Catalyst Pharma disclosed 42 risk factors in its most recent earnings report. Catalyst Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Catalyst Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$3.98B18.3333.18%22.42%
76
Outperform
$2.71B13.9128.49%29.97%178.11%
61
Neutral
$5.02B-48.54%42.77%-51.27%
58
Neutral
$5.06B-25.34%-86.13%-67.29%
56
Neutral
$5.82B-1334.54%53.55%30.87%
51
Neutral
$7.39B0.36-62.86%2.36%15.48%-2.68%
49
Neutral
$2.65B-182.60%26.77%24.18%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CPRX
Catalyst Pharma
19.64
1.16
6.28%
ACAD
ACADIA Pharmaceuticals
24.40
8.77
56.11%
RARE
Ultragenyx Pharmaceutical
27.83
-22.20
-44.37%
MRUS
Merus
63.39
12.65
24.93%
CRSP
Crispr Therapeutics AG
55.96
8.95
19.04%
RYTM
Rhythm Pharmaceuticals
92.48
47.22
104.33%

Catalyst Pharma Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Catalyst Pharma Updates Guidelines for SCLC Treatment
Positive
Aug 7, 2025

On August 6, 2025, Catalyst Pharmaceuticals announced that the National Comprehensive Cancer Network Clinical Practice Guidelines for Small Cell Lung Cancer now include Lambert Eaton myasthenic syndrome (LEMS), amifampridine, and tests for voltage-gated calcium channel antibodies. This update aims to improve diagnosis and treatment of LEMS in SCLC patients, potentially enhancing patient outcomes by raising clinical awareness and promoting comprehensive neurological evaluations.

The most recent analyst rating on (CPRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Catalyst Pharma Reports Record Q2 2025 Financial Results
Positive
Aug 6, 2025

On August 6, 2025, Catalyst Pharmaceuticals reported record financial results for the second quarter and first half of 2025, with total revenues reaching $146.6 million in Q2, marking a 19.4% year-over-year increase. The company highlighted strong performance across its product portfolio, particularly noting AGAMREE’s significant growth following its 2024 launch, while FYCOMPA faced a slight revenue decline due to generic competition. Catalyst’s robust cash position and reaffirmed revenue guidance reflect its strategic execution and sustained demand, positioning it well for future growth.

The most recent analyst rating on (CPRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
Catalyst Pharma Appoints Dr. Curran to Board
Positive
Aug 4, 2025

On August 4, 2025, Catalyst Pharmaceuticals announced the appointment of Dr. Daniel J. Curran to its Board of Directors, expanding the board from six to seven members. Dr. Curran brings over 25 years of experience in the pharmaceutical industry, with expertise in strategy, business development, and rare disease therapies. His appointment is expected to bolster Catalyst’s growth strategy, focusing on maximizing its rare disease portfolio and acquiring strategically aligned assets.

The most recent analyst rating on (CPRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Executive/Board Changes
Catalyst Pharma Appoints New Chief Medical Officer
Neutral
Jun 2, 2025

On June 1, 2025, Catalyst Pharmaceuticals announced the retirement of its Chief Medical and Regulatory Officer, Dr. Gary Ingenito, who will continue as a consultant to aid in the transition. Dr. William Andrews was appointed as the new Chief Medical Officer on June 2, 2025, bringing 25 years of global biopharmaceutical experience, particularly in rare diseases, to the company. Dr. Andrews’s extensive background includes leadership roles in clinical development, medical affairs, and business development, positioning Catalyst to continue its growth and success in the biopharmaceutical industry.

The most recent analyst rating on (CPRX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Catalyst Pharma Holds 2025 Annual Stockholders Meeting
Neutral
May 23, 2025

At Catalyst Pharma‘s 2025 Annual Meeting of Stockholders on May 20, 2025, several directors were elected to the Board, including Richard J. Daly, Patrick J. McEnany, Donald A. Denkhaus, Molly Harper, Tamar Thompson, and David S. Tierney, to serve until the 2026 meeting. Charles B. O’Keeffe, a long-standing independent board member, retired without any disagreements with the company. Additionally, the meeting saw the approval of an amendment to the 2018 Stock Incentive Plan, the 2024 executive compensation, and the ratification of Grant Thornton, LLP as the independent accounting firm for 2025.

The most recent analyst rating on (CPRX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 08, 2025